



Year: 2015

Sequencing of plasmids pAMBL1 and pAMBL2 from *Pseudomonas aeruginosa* reveals a blaVIM-1 amplification causing high-level carbapenem resistance

San Millan, Alvaro ; Toll-Riera, Macarena ; Escudero, Jose Antonio ; Cantón, Rafael ; Coque, Teresa M ; MacLean, R Craig

Abstract: **BACKGROUND:** Carbapenemases are a major concern for the treatment of infectious diseases caused by Gram-negative bacteria. Although plasmids are responsible for the spread of resistance genes among these pathogens, there is limited information on the nature of the mobile genetic elements carrying carbapenemases in *Pseudomonas aeruginosa*. **METHODS:** We combined data from two different next-generation sequencing platforms, Illumina HiSeq2000 and PacBio RSII, to obtain the complete nucleotide sequences of two blaVIM-1-carrying plasmids (pAMBL1 and pAMBL2) isolated from *P. aeruginosa* clinical isolates. **RESULTS:** Plasmid pAMBL1 has 26 440 bp and carries a RepA_C family replication protein. pAMBL1 is similar to plasmids pNOR-2000 and pKLC102 from *P. aeruginosa* and pAX22 from *Achromobacter xylosoxidans*, which also carry VIM-type carbapenemases. pAMBL2 is a 24 133 bp plasmid with a replication protein that belongs to the Rep₃ family. *It shows a high degree of homology with a fragment of the blaVIM-1-bearing plasmid pPC9 from Pseudomonas putida. Plasmid pAMBL2 carries three copies of the blaVIM-1 cassette in an In70 class 1 integron conferring, unlike pAMBL1, high-level resistance to carbapenems.* **CONCLUSIONS:** We present two new plasmids coding for VIM-1 carbapenemase from *P. aeruginosa* and report that the presence of three copies in pAMBL2 produces high-level resistance to carbapenems.

DOI: <https://doi.org/10.1093/jac/dkv222>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-120875>

Journal Article

Accepted Version

Originally published at:

San Millan, Alvaro; Toll-Riera, Macarena; Escudero, Jose Antonio; Cantón, Rafael; Coque, Teresa M; MacLean, R Craig (2015). Sequencing of plasmids pAMBL1 and pAMBL2 from *Pseudomonas aeruginosa* reveals a blaVIM-1 amplification causing high-level carbapenem resistance. *Journal of Antimicrobial Chemotherapy*, 70(11):3000-3003.

DOI: <https://doi.org/10.1093/jac/dkv222>

1 **Sequencing of plasmids pAMBL1 and pAMBL2 from *Pseudomonas***
2 ***aeruginosa* reveals a *bla*_{VIM-1} amplification causing high-level**
3 **carbapenem resistance**

4 Alvaro **San Millan** ^{1,*}, Macarena **Toll-Riera** ^{1,Φ}, Jose Antonio **Escudero** ²,
5 Rafael **Cantón** ³, Teresa M **Coque** ^{3,4}, R Craig **MacLean** ¹

6 ¹Department of Zoology, University of Oxford, South Parks Road. OX1 3PS,
7 Oxford, United Kingdom

8 ² Institut Pasteur, Plasticité du Génome Bactérien, CNRS URA 2171, 75015
9 Paris, France

10 ³ Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto
11 Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Unidad
12 de Resistencia a Antibióticos y Virulencia Bacteriana asociada al Consejo
13 Superior de Investigaciones Científicas (CSIC), Madrid, Spain

14 ⁴ Centros de Investigación Biomédica en Red de Epidemiología y Salud
15 Pública, (CIBER-ESP), Spain

16 ^Φ Current affiliation: Institute of Evolutionary Biology and Environmental
17 Studies, University of Zurich, 8057, Zurich, Switzerland

18 * Correspondence to: e-mail, alvaro.sanmillan@zoo.ox.ac.uk. Phone, +44
19 07402 23 10 13.

20 Running title: Characterization of plasmids pAMBL1 and pAMBL2.

21 Keywords: Plasmid-mediated resistance, VIM, carbapenemase, antibiotic
22 multiresistance, *Pseudomonas aeruginosa*, gene amplification.

23 **Synopsis**

24 Objectives: Carbapenemases are a major concern for the treatment of
25 infectious diseases produced by Gram-negative bacteria. Although
26 plasmids are responsible for the spread of resistance genes among these
27 pathogens, there is limited information on the nature of the mobile genetic
28 elements carrying carbapenemases in *Pseudomonas aeruginosa*.

29 Methods: We combined data from two different next generation
30 sequencing platforms, Illumina HiSeq2000 and PacBio RSII, to obtain the
31 complete nucleotide sequence of two *bla*_{VIM-1}-carrying plasmids (pAMBL1
32 and pAMBL2) isolated from *P. aeruginosa* clinical isolates.

33 Results: Plasmid pAMBL1 has 26,440 bp and carries a RepA_C family
34 replication protein. pAMBL1 is similar to plasmids pNOR-2000 and pKLC102
35 from *P. aeruginosa* and pAX22 from *Achromobacter xylosoxidans*, which
36 also carry VIM-type carbapenemases. pAMBL2 is a 24,133 bp plasmid with
37 a replication protein that belongs to the Rep_3 family. It shows high degree
38 of homology with a fragment of the *bla*_{VIM-1}-bearing plasmid pPC9 from
39 *Pseudomonas putida*. Plasmid pAMBL2 carries three copies of the *bla*_{VIM-1}
40 cassette in an In70 class 1 integron conferring, unlike pAMBL1, high level
41 resistance to carbapenems.

42 Conclusions: Here we present two new plasmids coding for VIM-1
43 carbapenemase from *P. aeruginosa* and we report that the presence of
44 three copies of *bla*_{VIM-1} in pAMBL2 produces high-level resistance to
45 carbapenems.

46 **Introduction**

47 *P. aeruginosa* produces opportunistic infections that are hard to treat due
48 to its great ability to develop resistance to antibiotics. Although
49 chromosomally-encoded resistance mechanisms are often responsible for
50 this phenotype,¹ plasmids also play a key role in the acquisition of
51 antibiotic multi-drug-resistance in this species. Plasmids from *P.*
52 *aeruginosa* often carry the same antibiotic resistance genes found on
53 mobile genetic elements from Enterobacteriaceae. Among these genes,
54 those encoding metallo- β -lactamases such as VIM-type enzymes are
55 specially important since they can hydrolyse all β -lactams including
56 carbapenems, one of the last resorts of therapeutic treatment for
57 infections caused by Enterobacteriaceae. Despite their clinical
58 significance, there is little information available on the nature of plasmids
59 carrying carbapenemases in *P. aeruginosa*,² or on the routes of
60 dissemination of these resistance genes between pseudomonas and
61 enterobacteria.

62 pAMBL1 and pAMBL2 are two *bla*_{VIM-1}-carrying plasmids recovered from *P.*
63 *aeruginosa* clinical isolates at the *Ramon y Cajal University Hospital* in
64 Madrid, Spain, in 2006-2007, during an outbreak of VIM-producing
65 bacteria.³ Here, we combined Illumina HiSeq2000 and PacBio RSII
66 technologies to determine the complete nucleotide sequence of pAMBL1
67 and pAMBL2. This strategy allowed us to detect three copies of *bla*_{VIM-1} β -
68 lactamase gene inside an integron in pAMBL2, which conferred high-level
69 resistance to meropenem in *P. aeruginosa* PAO1.

70 **Materials and methods**

71 *Bacterial strains, culture conditions and antibiotic susceptibility testing.*

72 Plasmid pAMBL1 and pAMBL2 were recovered from *P. aeruginosa* isolates
73 in the pneumology ward in 2006 and in the urology ward in 2007,
74 respectively, at the *Ramon y Cajal University Hospital* in Madrid.³ Bacterial
75 strains were cultured in LB broth at 37°C (225 rpm) and on Luria Bertani
76 agar plates at 37°C (Fisher Scientific, USA). Plasmids were electroporated
77 into *P. aeruginosa* PAO1.⁴ Transformants were selected on plates with
78 carbenicillin 256 mg/L and ceftazidime 50 mg/L. We performed conjugation
79 experiments as previously described³ using a GFP-tagged *P. aeruginosa*
80 PAO1 (chloramphenicol and gentamicin resistant)⁴ as a recipient strain and
81 PAO1/pAMBL1 and PAO1/pAMBL2 as donors. Susceptibility testing was
82 performed by broth microdilution method according to the CLSI
83 guidelines.⁵ The MICs were determined as the mean of three or four
84 independent experiments (Table 1).

85 *DNA analysis, sequencing and bioinformatics*

86 DNA samples were obtained using Qiagen Dneasy Blood and Tissue Kit
87 (Qiagen, USA) and quantified using QuantiFluor dsDNA system (Promega,
88 USA). Library preparation and sequencing was performed at the Wellcome
89 Trust Centre for Human Genetics, University of Oxford (using HiSeq2000
90 and 100-bp-paired end reads, average median depth of coverage 70x) and
91 at The Genome Analysis Centre in Norwich (PacBio RS platform using P5-
92 C3 chemistry, average median depth of coverage 50x). To assemble de
93 novo the paired end reads obtained with Illumina technology we used A5
94 pipeline (developed for microbial genomes).⁶ We used Geneious 7.1.7
95 (Biomatters, USA) to analyse the reads from PacBio. To annotate the
96 plasmids we used RAST server,⁷ and confirmed the annotation doing
97 BLASTP similarity searches of each predicted protein. Plasmid sequences

98 were confirmed by restriction profile with endonucleases *HindIII*, *EcoRI*,
99 *XhoI*, *KpnI*, *BamHI* (New England BioLabs, USA), by PCR mapping and by
100 Sanger sequencing the complete integron in pAMBL2 and all the
101 ambiguous residues (Table S1). RNA extraction and RNA-Seq analysis were
102 performed as described in San Millan *et al.* 2015.⁸

103

104

105 **Results and discussion**

106 *Sequencing of plasmids pAMBL1 and pAMBL2*

107 We transformed *P. aeruginosa* PAO1 with plasmid pAMBL1 and pAMBL2.⁴ To
108 determine the complete nucleotide sequence of the plasmids, we
109 extracted the genomic DNA from PAO1/pAMBL1 and PAO1/pAMBL2 and
110 sequenced the samples using Illumina HiSeq2000. After filtering PAO1
111 chromosomal DNA and assembling the remaining reads, we obtained a
112 single contig for pAMBL1 that was manually closed to a circle. However,
113 for pAMBL2 we obtained two non-overlapping contigs, which could not be
114 linked by PCR. A limitation of assembling bacterial genomes using Illumina
115 technology is that reads are short (ca. 100bp), and this affects the power
116 to assemble DNA regions containing long repeats and duplications.⁹
117 Therefore, we sequenced both DNA samples using PacBio RSII technology,
118 which has a higher error rate than the Illumina technology but produces
119 longer reads (average= 6kb). PacBio data helped solving the overall
120 structure of the plasmids. By combining the results obtained with the two
121 platforms, we were able to determine the exact nucleotide sequence of
122 plasmids pAMBL1 and pAMBL2.

This work enlarges the list of plasmids from *P. aeruginosa*, which despite the relevance of this species as opportunistic pathogen, are underrepresented in the plasmid genome database (<http://www.ncbi.nlm.nih.gov/genome/?term=pseudomonas+aeruginosa>).

Analysis of pAMBL1

pAMBL1 conferred resistance to gentamicin, carbenicillin, ceftazidime, meropenem and mercury in *P. aeruginosa* PAO1 (Table 1) and was not able to conjugate under our experimental conditions. It was 26,440 bp in size, had an average GC content of 63.5% and contained 29 ORFs (Figure 1a). This plasmid carried a replication protein belonging to the RepA_C family and presented a backbone structure containing the replication, partitioning and mobilization genes which was very similar to the equivalent region in three plasmids: (i) the *bla*_{VIM-2} carrying plasmid pNOR-2000 from *P. aeruginosa*,¹⁰ (ii) plasmid pAX22 from *Achromobacter xylosoxidans*, which also carries *bla*_{VIM-1},¹¹ and (iii) TnCP23, a plasmid inserted into the chromosomally integrated element pKLC102 of *P. aeruginosa* strain C¹² (Figure 1a). pAMBL1 also carried a Tn5563a element,¹³ inserted in the *traG* gene, carrying putative mercury resistance genes (Table 1), and a defective Tn402 transposon carrying *aadB* and *bla*_{VIM-1} cassettes in a class 1 integron. Additionally, pAMBL1 also harboured a serine protease gene, *degP*, similar to the one in pNOR-2000,¹⁰ and a putative efflux pump and its transcriptional regulator showing 99% nucleotide identity with those found in *Enterobacter* spp. plasmid pENT01 (Accession NC_021492.1).

Analysis of pAMBL2

148 Plasmid pAMBL2 conferred resistance to streptomycin, kanamycin,
149 carbenicillin, ceftazidime and meropenem in PAO1 (Table 1) and it was
150 unable to conjugate. This plasmid presented a length of 24,133 bp, with an
151 average GC content of 60.4%, and it coded for 35 predicted ORFs
152 including a Rep_3 family replication protein. pAMBL2 was very similar to a
153 segment of pPC9, an 80 kb multi-drug resistance plasmid from a clinical
154 isolate of *Pseudomonas putida*¹⁴. pAMBL2 backbone was also similar to
155 pCT14 from a *Pseudomonas* spp. isolated from activated sludge (Figure
156 1b).¹⁵ Apart from the replication and partitioning genes, pAMBL2 also
157 carried an ISPa17 element coding for a toxin-antitoxin system.¹⁶ ISPa17
158 has been suggested to mobilize defective Tn402-like transposons carrying
159 class 1 integrons.¹¹ We found that pAMBL2 contained three copies of the
160 *bla*_{VIM-1} carbapenemase gene cassette inside the In70 class 1 integron,
161 which also carried *aacA4*, *aadA1*, *qacEΔ1* and *sul1* cassettes.

162 Interestingly, pAMBL2 conferred high-level resistance to meropenem in *P.*
163 *aeruginosa* PAO1 (MIC, average= 192 mg/L, SD=74 mg/L, n= 4). Actually,
164 meropenem resistance was higher in PAO1/pAMBL2 than in PAO1/pAMBL1
165 (MIC, average= 80 mg/L, SD=32, n=4), which carries only one copy of
166 *bla*_{VIM-1} (Paired *t*-test, *P*= 0.035, *t*₃= -3.66). Given that these two plasmids
167 carry *bla*_{VIM-1} in class 1 integrons with identical promoters for the
168 expression of the cassettes (PcW),¹⁷ and that both plasmids have similar
169 copy numbers in PAO1,⁴ this result suggested that the triplication of *bla*_{VIM-1}
170 is responsible for the increase in meropenem resistance. To confirm this
171 hypothesis we used RNA-Seq (data from San Millan *et al.*, in preparation)
172 to measure the transcription of *bla*_{VIM-1}. This analysis revealed a 34%
173 increase in the transcription levels of *bla*_{VIM-1} in PAO1/pAMBL2 compared to
174 PAO1/pAMBL1. In addition, we performed a nitrocefin test¹⁸ (a colorimetric

175 assay that quantifies β -lactamase activity) with PAO1/pAMBL1 and
176 PAO1/pAMBL2, and we observed a 1.54-fold increase in β -lactamase
177 activity in PAO1/pAMBL2 compared to PAO1/pAMBL1 (data not shown).
178 These experiments confirmed that the amplification of *bla*_{VIM-1} in pAMBL2 is
179 responsible for the high-level meropenem resistance phenotype in
180 PAO1/pAMBL2.

181 Our results suggest that metallo- β -lactamase amplification could drive
182 high-level carbapenem resistance in nature. This type of amplifications
183 could be responsible for the carbapenem heteroresistance previously
184 described in clonally-related Enterobacteriaceae clinical isolates carrying
185 the *bla*_{VIM-1} gene.¹⁹

186 **Conclusion**

187 Duplication of cassettes in integrons has rarely been described before,²⁰
188 but this could be partially due to limitations of the sequencing technology.
189 Because of the semiconservative nature of cassette recombination,
190 integron integrases can duplicate cassettes within the array.^{21, 22} Therefore,
191 cassette duplications may be more frequent in nature than previously
192 expected. The amplification of an antibiotic resistance cassette can
193 potentially increase the antibiotic resistance level, as we have observed in
194 this work. In addition, duplications pave the way for subsequent
195 evolutionary steps such as the neo-functionalization or sub-
196 functionalization of the copies, and this could play a key role in the
197 evolution of antibiotic resistance.²³ The improvement in the sequencing
198 technologies and the combination of several techniques will enhance the
199 identification of duplications, increasing the quality and completeness of
200 assembled genomes,⁹ and enhancing our understanding of the role of

201 integrons in the evolution of antibiotic resistance. Finally, pAMBL1 and
202 pAMBL2 enlarge the list of plasmids with RepA_C and Rep3 replication
203 proteins described in *Pseudomonas* species, which seem to have
204 remarkable interest for epidemiological purposes.

205 **Acknowledgements**

206 We thank the High-Throughput Genomics Group at the Wellcome Trust
207 Centre for Human Genetics funded by Wellcome Trust grant reference
208 090532/Z/09/Z and Medical Research Council Hub grant G0900747 91070
209 for generation of the high-throughput sequencing data.

210 **Funding**

211 This work was supported by the European Research Council under the
212 European Union's Seventh Framework Programme (FP7/2007-2013)/ERC
213 grant (StG-2011-281591) and from the Royal Society. Two Marie Curie
214 Intra-European Fellowships within the Seventh European Community
215 Framework Programme supported the work of ASM (PIEF-GA-2011-298975)
216 and JAE (PIEF-GA-2011-303022). Research in the IRYCIS group is funded by
217 the European Commission (R-GNOSIS-FP7-HEALTH-F3-2011-282512), the
218 Regional Government of Madrid in Spain (PROMPT-S2010/BMD2414), and
219 by the Spanish Network for Research on Infectious Diseases (REIPI
220 RD12/0015).

221 **Transparency declarations**

222 Nothing to declare

223 **Nucleotide sequence accession number**

224 The nucleotide sequences of pAMBL1 and pAMBL2 have been deposited in
225 GenBank under the accession numbers KP873172 and KP873171,
226 respectively, and the analysis of the integrons is available in INTEGRALL
227 database.²⁴

228 References


- 229 1. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant
230 *Pseudomonas aeruginosa*: clinical impact and complex regulation of
231 chromosomally encoded resistance mechanisms. *Clin Microbiol Rev* 2009;
232 **22**: 582-610.
- 233 2. Shintani M, Sanchez ZK, Kimbara K. Genomics of microbial plasmids:
234 classification and identification based on replication and transfer systems
235 and host taxonomy. *Front Microbiol* 2015; **6**: 242.
- 236 3. Tato M, Coque TM, Baquero F et al. Dispersal of carbapenemase
237 blaVIM-1 gene associated with different Tn402 variants, mercury
238 transposons, and conjugative plasmids in Enterobacteriaceae and
239 *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2010; **54**: 320-7.
- 240 4. San Millan A, Heilbron K, MacLean RC. Positive epistasis between co-
241 infecting plasmids promotes plasmid survival in bacterial populations.
242 *ISME J* 2014; **8**: 601-12.
- 243 5. Clinical and Laboratory Standards Institute. *Performance Standards*
244 *for Antimicrobial Susceptibility Testing: Nineteenth Informational*
245 *Supplement. M100-S19*. CLSI, Wayne, PA, USA, 2009.
- 246 6. Tritt A, Eisen JA, Facciotti MT et al. An integrated pipeline for de novo
247 assembly of microbial genomes. *PLoS One* 2012; **7**: e42304.
- 248 7. Aziz RK, Bartels D, Best AA et al. The RAST Server: rapid annotations
249 using subsystems technology. *BMC Genomics* 2008; **9**: 75.
- 250 8. San Millan A, Toll-Riera M, Qi Q et al. Interactions between
251 horizontally acquired genes create a fitness cost in *Pseudomonas*
252 *aeruginosa*. *Nat Commun* 2015; **6**: 6845.
- 253 9. Alkan C, Sajjadian S, Eichler EE. Limitations of next-generation
254 genome sequence assembly. *Nat Methods* 2011; **8**: 61-5.
- 255 10. Bonnin RA, Poirel L, Nordmann P et al. Complete sequence of broad-
256 host-range plasmid pNOR-2000 harbouring the metallo- β -lactamase gene
257 blaVIM-2 from *Pseudomonas aeruginosa*. *J Antimicrob Chemother* 2013;
258 **68**: 1060-5.
- 259 11. Di Pilato V, Pollini S, Rossolini GM. Characterization of plasmid
260 pAX22, encoding VIM-1 metallo- β -lactamase, reveals a new putative
261 mechanism of In70 integron mobilization. *J Antimicrob Chemother* 2014;
262 **69**: 67-71.
- 263 12. Klockgether J, Reva O, Larbig K et al. Sequence analysis of the
264 mobile genome island pKLC102 of *Pseudomonas aeruginosa* C. *J Bacteriol*
265 2004; **186**: 518-34.
- 266 13. Szuplewska M, Ludwiczak M, Lyzwa K et al. Mobility and generation
267 of mosaic non-autonomous transposons by Tn3-derived inverted-repeat
268 miniature elements (TIMEs). *PLoS One* 2014; **9**: e105010.
- 269 14. Molina L, Udaondo Z, Duque E et al. Antibiotic resistance
270 determinants in a *Pseudomonas putida* strain isolated from a hospital.
271 *PLoS One* 2014; **9**: e81604.

- 272 15. Bramucci M, Chen M, Nagarajan V. Genetic organization of a plasmid
273 from an industrial wastewater bioreactor. *Appl Microbiol Biotechnol* 2006;
274 **71**: 67-74.
- 275 16. Arcus VL, McKenzie JL, Robson J et al. The PIN-domain ribonucleases
276 and the prokaryotic VapBC toxin-antitoxin array. *Protein Eng Des Sel* 2011;
277 **24**: 33-40.
- 278 17. Jové T, Da Re S, Denis F et al. Inverse correlation between promoter
279 strength and excision activity in class 1 integrons. *PLoS Genet* 2010; **6**:
280 e1000793.
- 281 18. O'Callaghan CH, Morris A, Kirby SM et al. Novel method for detection
282 of beta-lactamases by using a chromogenic cephalosporin substrate.
283 *Antimicrob Agents Chemother* 1972; **1**: 283-8.
- 284 19. Tato M, Morosini M, García L et al. Carbapenem Heteroresistance in
285 VIM-1-producing *Klebsiella pneumoniae* isolates belonging to the same
286 clone: consequences for routine susceptibility testing. *J Clin Microbiol*
287 2010; **48**: 4089-93.
- 288 20. Stokes HW, Hall RM. The integron In1 in plasmid R46 includes two
289 copies of the oxa2 gene cassette. *Plasmid* 1992; **28**: 225-34.
- 290 21. Loot C, Ducos-Galand M, Escudero JA et al. Replicative resolution of
291 integron cassette insertion. *Nucleic Acids Res* 2012; **40**: 8361-70.
- 292 22. Escudero JA, Loot C, Nivina A et al. The integron: adaptation on
293 demand. *Microbiol Spectrum* 2015; **3**: 10.1128/microbiolspec.MDNA3-
294 0019-2014.
- 295 23. Taylor JS, Raes J. Duplication and divergence: the evolution of new
296 genes and old ideas. *Annu Rev Genet* 2004; **38**: 615-43.
- 297 24. Moura A, Soares M, Pereira C et al. INTEGRALL: a database and
298 search engine for integrons, integrases and gene cassettes. *Bioinformatics*
299 2009; **25**: 1096-8.

300

301 **Figures**

302 Figure 1. Plasmids pAMBL1 and pAMBL2



303

304 Schematic representation of plasmids (a) pAMBL1 and (b) pAMBL2. The
305 reading frames for genes are shown as arrows, with the direction of
306 transcription indicated by the arrowhead. Green arrows represent genes
307 involved in plasmid housekeeping functions such as replication, partition,

308 stability or conjugation. Red arrows indicate genes responsible for DNA
309 rearrangements (such as transposases or integrases). Blue arrows
310 represent accessory genes coding for selectable traits (including antibiotic
311 resistance). Genes of unknown function are shown in grey. The inner
312 circles represent regions of homology with previously described plasmids
313 (>80% of nucleotide identity). In panel a, the outer dark grey circle
314 represents plasmid TnCP23 from *P. aeruginosa*, the middle circle
315 corresponds to plasmid pAX22 from *A. xylosoxidans* and the inner light
316 grey circle represents plasmid pNOR-2000 from *P. aeruginosa*. In panel b,
317 the outer dark grey circle represents plasmid pPC9 from *P. putida*. The
318 middle circle corresponds to plasmid pAX22 from *A. xylosoxidans* and the
319 inner light grey circle represents plasmid pCT14 from *Pseudomonas* spp.
320 This figure appears in colour in the online version of JAC and in black and
321 white in the printed version of JAC.

322 Tables

323 Table 1. Antibiotic susceptibility profile of the strains used in this study

| Strain | Minimal inhibitory concentration (mg/L) | | | | | | |
|------------------------------|---|-----|-----|------------|-----------|-----|-----|
| | STR | GEN | KAN | CAR | CAZ | MER | Hg |
| <i>P. aeruginosa</i> PAO1 | 8 | 0.2 | 171 | 53 | 1 | 0.5 | 0.7 |
| PAO1/ pAMBL1 | 16 | 85 | 256 | 8,192 | 683 | 80 | 5 |
| PAO1/ pAMBL2 | 2,04 8 | 13 | 512 | 16,38 4 | 1,36 5 | 192 | 0.5 |

324

325 The minimal inhibitory concentrations are the mean of three or four
 326 independent experiments. STR, streptomycin; GEN, gentamicin; KAN,
 327 kanamycin; CAR, carbenicillin; CAZ, ceftazidime; MER, meropenem; Hg,
 328 mercury. The data of this table has been partially retrieved from the
 329 supplementary information of San Millan *et al.* 2014.⁴